CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF

Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositio...

Full description

Saved in:
Bibliographic Details
Main Authors CONNOR, Eric F, PENNELL, Andrew M. K, GOTTSCHLING, Stephen Edmund, KHAN, Mohammed Asadullah, COLOMVAKOS, Jim Dimetrios
Format Patent
LanguageEnglish
French
Published 23.12.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase is also provided. Des formes cristallines du composé de formule (I), qui module la conversion de l'AMP en adénosine par la 5'-nucléotidase, ainsi que des compositions contenant le composé et des procédés de préparation des formes cristallines sont décrits dans la description de la présente invention. L'invention concerne également l'utilisation d'une telle forme cristalline de formule (I) et des compositions dans le traitement et/ou la prévention d'un ensemble varié de maladies, troubles et affections, y compris du cancer et de troubles liés à l'immunité, qui sont médiés par la 5'-nucléotidase.
Bibliography:Application Number: WO2021US37535